Repligen Co. (NASDAQ:RGEN) Shares Sold by Advisors Asset Management Inc.

Advisors Asset Management Inc. lessened its holdings in Repligen Co. (NASDAQ:RGEN) by 1.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 9,091 shares of the biotechnology company’s stock after selling 102 shares during the period. Advisors Asset Management Inc.’s holdings in Repligen were worth $1,353,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Toronto Dominion Bank boosted its holdings in Repligen by 1.5% in the 2nd quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company’s stock worth $656,000 after acquiring an additional 75 shares during the period. DekaBank Deutsche Girozentrale boosted its stake in shares of Repligen by 1.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company’s stock valued at $982,000 after purchasing an additional 89 shares during the period. Ballentine Partners LLC grew its holdings in Repligen by 6.2% during the 3rd quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company’s stock valued at $269,000 after purchasing an additional 105 shares in the last quarter. Diversified Trust Co grew its holdings in Repligen by 3.7% during the 2nd quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company’s stock valued at $372,000 after purchasing an additional 106 shares in the last quarter. Finally, CWM LLC increased its stake in Repligen by 36.3% during the 3rd quarter. CWM LLC now owns 428 shares of the biotechnology company’s stock worth $64,000 after buying an additional 114 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Stock Up 2.4 %

RGEN stock opened at $146.06 on Tuesday. The firm has a fifty day moving average price of $140.26 and a two-hundred day moving average price of $143.12. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $211.13. The firm has a market cap of $8.18 billion, a price-to-earnings ratio of -394.59, a PEG ratio of 4.29 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. During the same quarter in the prior year, the business earned $0.23 earnings per share. Repligen’s quarterly revenue was up 9.7% on a year-over-year basis. Research analysts predict that Repligen Co. will post 1.52 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. JPMorgan Chase & Co. upped their price objective on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 31st. Stephens restated an “overweight” rating and set a $170.00 price objective on shares of Repligen in a research note on Tuesday, July 30th. UBS Group cut their target price on Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. Wolfe Research initiated coverage on shares of Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. Finally, Wells Fargo & Company assumed coverage on shares of Repligen in a report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price target on the stock. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $190.25.

Insider Transactions at Repligen

In other news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares in the company, valued at approximately $20,328,540.80. This represents a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.